Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04379518
Recruitment Status : Recruiting
First Posted : May 7, 2020
Last Update Posted : March 2, 2022
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 17, 2023
Estimated Study Completion Date : November 17, 2023